Risk of SARS-CoV-2 infection during the omicron surge in patients on dialysis


In a recent study published in Journal of the American Society of Nephrology, a third COVID-19 mRNA vaccine dose in adults with kidney failure who were on dialysis enhanced patients’ protection against SARS-CoV-2 infection during the omicron-dominant period. A patient’s response to vaccination or prior infection—as measured by circulating anti-SARS-CoV-2 antibody levels—was also an important predictor for subsequent risk of infection.

In the study of randomly-selected patients receiving dialysis in the United States, a team led by Shuchi Anand, MD, MS, Pablo Garcia, MD, MS, and Maria Montez Rath, Ph.D. (Stanford University School of Medicine) followed patients’ monthly anti–SARS-CoV-2 antibody levels and ascertained COVID-19 infection during the omicron- dominant period of December 25, 2021 to January 31, 2022 using electronic health records.

Among 3,576 patients receiving dialysis, 901 (25%) received a third mRNA vaccine dose as of December 1, 2022, and early antibody responses to third doses were robust. During the omicron-dominant period, SARS-CoV-2 infection was documented in 340 (7%) patients. Risk for infection was doubled among patients without vaccination and nearly 1.5-fold higher with 1–2 doses compared with 3 doses. Irrespective of vaccine doses, risk for infection was at least 2-fold higher among patients with low circulating levels of anti–SARS-CoV-2 antibodies.

Source: Read Full Article